IMMUPHARMA UPDATES ON CANCER COMPOUND PHASE I/IIA CLINICAL TRIAL

ImmuPharma, a discovery and development pharmaceutical company, said around half of the cancer patients that have undergone treatment with its drug candidate IPP-204106 are in stable condition (their disease has stopped progressing) without any other drug treatment.ImmuPharma's clinical trial began last summer and up to now two lower dose levels have been tested.

The initial dose level of 1 mg/kg did not show any drug-related side effects.The first patient to be treated in this study is still alive and with stable disease 8 months after starting treatment with ImmuPharma's cancer compound.The second dose level of 2 mg/kg also did not show any drug-related side effects.

ImmuPharma has already begun development of the next generation of IPP-204106, the 'micro Nucants'.

This improved formulation comprising of small particles of the drug candidate has shown an even more impressive efficacy in cancer models.The clinical trial is taking place in two hospitals in Paris and one hospital in Dijon, in France and is expected to complete in the coming months.ImmuPharma hopes to start a Phase IIb programme later this year in patients with glioblastoma (brain tumour), hormone-resistant prostate cancer and pancreatic cancer.ImmuPharma CEO Dimitri Dimitriou said the latest positive results of their cancer drug candidate clinical trial puts the company in a good position for further major corporate deals such as the one with their partner Cephalon on Lupuzor that is now in a large late-stage clinical trial in the US.